Investigational treatment reduces hepcidin, potentially beneficial to patients with anemia

AUSTIN, Texas —An investigational treatment, DISC-0974, can reduce hepcidin and elevate iron levels in healthy patients, according to a presenter at the National Kidney Foundation Spring Clinical Meetings.
This may lead to therapeutic benefits for patients with chronic kidney disease and anemia.
“DISC-0974 is an investigational first-in-class monoclonal antibody-targeting hemojuvelin (HJV) to suppress the production of hepcidin and make iron available for red blood cell production. Pathologic elevations in hepcidin, a central regulator of iron homeostasis, contributes to anemia in

AUSTIN, Texas —An investigational treatment, DISC-0974, can reduce hepcidin and elevate iron levels in healthy patients, according to a presenter at the National Kidney Foundation Spring Clinical Meetings.
This may lead to therapeutic benefits for patients with chronic kidney disease and anemia.
“DISC-0974 is an investigational first-in-class monoclonal antibody-targeting hemojuvelin (HJV) to suppress the production of hepcidin and make iron available for red blood cell production. Pathologic elevations in hepcidin, a central regulator of iron homeostasis, contributes to anemia in